DE60027364D1 - Adenovirus-mutanten mit deletiertem proteasegen, komplementierende zelllinien und entsprechende vektoren für den gentransfer - Google Patents

Adenovirus-mutanten mit deletiertem proteasegen, komplementierende zelllinien und entsprechende vektoren für den gentransfer

Info

Publication number
DE60027364D1
DE60027364D1 DE60027364T DE60027364T DE60027364D1 DE 60027364 D1 DE60027364 D1 DE 60027364D1 DE 60027364 T DE60027364 T DE 60027364T DE 60027364 T DE60027364 T DE 60027364T DE 60027364 D1 DE60027364 D1 DE 60027364D1
Authority
DE
Germany
Prior art keywords
deleted
protease
gene
positive selection
region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60027364T
Other languages
English (en)
Other versions
DE60027364T2 (de
Inventor
Bernard Massie
Wahiba Qualikene
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National Research Council of Canada
Original Assignee
National Research Council of Canada
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National Research Council of Canada filed Critical National Research Council of Canada
Application granted granted Critical
Publication of DE60027364D1 publication Critical patent/DE60027364D1/de
Publication of DE60027364T2 publication Critical patent/DE60027364T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10351—Methods of production or purification of viral material
    • C12N2710/10352—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C12N2830/003—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor tet inducible
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
DE60027364T 1999-02-25 2000-02-24 Adenovirus-mutanten mit deletiertem proteasegen, komplementierende zelllinien und entsprechende vektoren für den gentransfer Expired - Fee Related DE60027364T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/258,209 US6291226B1 (en) 1999-02-25 1999-02-25 Adenovirus mutants with deleted protease gene
US258209 1999-02-25
PCT/CA2000/000197 WO2000050619A1 (en) 1999-02-25 2000-02-24 Adenovirus mutants with deleted protease gene, complementing cell lines and corresponding vectors for gene transfer

Publications (2)

Publication Number Publication Date
DE60027364D1 true DE60027364D1 (de) 2006-05-24
DE60027364T2 DE60027364T2 (de) 2007-05-10

Family

ID=22979566

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60027364T Expired - Fee Related DE60027364T2 (de) 1999-02-25 2000-02-24 Adenovirus-mutanten mit deletiertem proteasegen, komplementierende zelllinien und entsprechende vektoren für den gentransfer

Country Status (6)

Country Link
US (2) US6291226B1 (de)
EP (2) EP1073760B1 (de)
AT (1) ATE323775T1 (de)
CA (1) CA2322222C (de)
DE (1) DE60027364T2 (de)
WO (1) WO2000050619A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6642052B2 (en) * 1999-02-25 2003-11-04 National Research Council Of Canada Efficient generation of adenovirus-based libraries by positive selection of adenoviral recombinants through ectopic expression of the adenovirus protease
US20040042961A1 (en) * 2002-07-31 2004-03-04 Robert Menard Development of an in vivo functional assay for proteases
US7935788B2 (en) * 2004-10-04 2011-05-03 National Research Council Of Canada Reverse cumate repressor mutant
WO2006037215A1 (en) 2004-10-04 2006-04-13 National Research Council Of Canada Expression system, components thereof and methods of use
EP2147105B1 (de) 2007-05-02 2013-04-24 Merial Limited Dna-plasmide mit verbesserter expression und stabilität
WO2019084384A1 (en) 2017-10-27 2019-05-02 Massachusetts Institute Of Technology METHODS AND COMPOSITIONS FOR CONTINUOUS DIRECTED EVOLUTION

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5543264A (en) 1990-06-29 1996-08-06 Associated Universities, Inc. Co-factor activated recombinant adenovirus proteinases
US5801029A (en) 1993-02-16 1998-09-01 Onyx Pharmaceuticals, Inc. Cytopathic viruses for therapy and prophylaxis of neoplasia
US5866755A (en) 1993-06-14 1999-02-02 Basf Aktiengellschaft Animals transgenic for a tetracycline-regulated transcriptional inhibitor
KR100356615B1 (ko) * 1993-07-13 2003-04-03 아방티 파르마 소시에테 아노님 결함아데노바이러스벡터및유전자치료에서그의사용
BR9508224A (pt) * 1994-07-14 1997-10-28 Union Camp Patent Holding Processo tendo seletividade aumentada para alvejamento de polpa lignocelulósica alvejada
US5972666A (en) 1996-07-26 1999-10-26 G. D. Searle & Co. Assembly-deficient herpesvirus vaccine
US5994134A (en) * 1998-05-04 1999-11-30 Canji, Inc. Viral production process

Also Published As

Publication number Publication date
EP1073760B1 (de) 2006-04-19
DE60027364T2 (de) 2007-05-10
US20010026938A1 (en) 2001-10-04
US6291226B1 (en) 2001-09-18
EP1291434A2 (de) 2003-03-12
ATE323775T1 (de) 2006-05-15
CA2322222A1 (en) 2000-08-31
CA2322222C (en) 2010-05-18
US6620618B2 (en) 2003-09-16
WO2000050619A1 (en) 2000-08-31
EP1291434A3 (de) 2003-12-03
EP1073760A1 (de) 2001-02-07

Similar Documents

Publication Publication Date Title
Schiedner et al. Efficient transformation of primary human amniocytes by E1 functions of Ad5: generation of new cell lines for adenoviral vector production
US5922576A (en) Simplified system for generating recombinant adenoviruses
ATE196502T1 (de) Neue komplementations-zelllinien für defekte adenovirale vektoren
DK0707071T3 (da) Rekombinante vektorer afledt fra adenovirus til anvendelse i genterapi
WO2000012740A3 (en) Adenoviruses deleted in the iva2, 100k and/or preterminal protein sequences
NO20045131L (no) Stabile adenovirale vektorer samt fremgangsmater ved formering derav
NO20042191L (no) Simian-adenovirusnukleinsyre og aminosyresekvenser, vektorer inneholdende disse, og fremgangsmater for deres anvendelse
DE60027364D1 (de) Adenovirus-mutanten mit deletiertem proteasegen, komplementierende zelllinien und entsprechende vektoren für den gentransfer
DK0988391T3 (da) Rekombinante adenovirusvektorer der omfatter en splejsningssekvens
EP3844286A1 (de) Kompetente viren mit rekombinanter replikation mit einem codierenden bereich für glykogensynthase-kinase-3 (gsk3) und verfahren zum abtöten von anormalen zellen
Oualikene et al. Protease-deleted adenovirus vectors and complementing cell lines: potential applications of single-round replication mutants for vaccination and gene therapy
Fu et al. Use of the cosmid adenoviral vector cloning system for the in vitro construction of recombinant adenoviral vectors
Richards et al. The admid system: generation of recombinant adenoviruses by Tn7-mediated transposition in E. coli
Ring Adenovirus vectors
Hillgenberg et al. System for efficient helper-dependent minimal adenovirus construction and rescue
Elahi et al. Effects of E3 and E4 Deletion on the Replication and Transgene Expression of Single Cycle Adenovirus Vector
DE60334222D1 (en) Adenovirusvektor
WO2001066715A3 (en) Rapid generation of recombinant adenoviral vectors
ITRM980694A1 (it) Cellule per la produzione di vettori adenovirali difettivi, metodo per la loro preparazione e loro uso.
Ugai et al. Accumulation of infectious mutants in stocks during the propagation of fiber-modified recombinant adenoviruses
Neuhierl et al. Molecular Genetics of DNA Viruses
Ohbayashi et al. 23. Frequency of Random and Targeted Chromosomal Integration of Helper-Dependent Adenoviral Vector
Zaratiegui et al. Method to decrease the titers of contaminating helper adenovirus during the production of recombinant adeno-associated virus

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee